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Introduction {#sec006}
============

In developed countries, breast cancer is a leading cause of cancer-related deaths in women aged 40 years and younger\[[@pone.0155597.ref001]\]. Early detection of breast cancer has been associated with reduced morbidity and mortality, compared to late detection\[[@pone.0155597.ref002]\]. In the early phase of breast cancer, breast cancer cells are mainly spread through the lymphatic system. Axillary lymph node dissection (ALND) has been used to evaluate lymph node status and identify the presence of metastases. However, ALND appears correlated with increased morbidity of lymphedema, pain, stiffness and shoulder weakness, seroma formation, vascular and brachial plexus injuries, and other complications. In patients with low-risk breast carcinoma, sentinel lymph node biopsy (SLNB) reportedly avoids ALND and thus reduces the complications associated with ALND\[[@pone.0155597.ref003]\].

Sentinel lymph nodes (SLNs) are the first lymph nodes that receive lymphatic drainage from the primary tumor \[[@pone.0155597.ref004]\]. SLNB is considered the standard care for patients without clinical or radiological evidence of axillary lymph node metastases in early-stage breast cancer\[[@pone.0155597.ref005]\]. A periareolar or interstitial injection of isotope and blue dye into the breast tumor is traditional in SLNB, and the 2 materials together are better than either alone \[[@pone.0155597.ref006]\].

A recent meta-analysis compared the traditional isotope-and-blue dye combination with 3 methods that are relatively new: indocyanine green fluorescence (ICG), contrast-enhanced ultrasound using microbubbles, and superparamagnetic iron oxide nanoparticles \[[@pone.0155597.ref004]\]. The newer methods showed clinical potential, but the false-negative rate of the compared methods ranged from zero for ICG to 30% for blue dye \[[@pone.0155597.ref004]\]. There was no ALND confirmation in some of the included studies, which potentially increased bias. Additionally, a jumping metastasis, or an abnormality in the lymphatic drainage pathway, makes a false negative inevitable, and an extrapolation of comparisons among different techniques is more difficult. In our opinion, the gold standard to identify whether a technique is reliable should be followed, that is, ALND plus histological or immunohistochemical confirmation.

In this study, we performed a meta-analysis to investigate the diagnostic performance of indocyanine green (ICG) fluorescence-guided SLNB in the presence of metastases in breast cancer, with ALND plus histological or immunohistochemical results as the reference.

Methods {#sec007}
=======

A systematic literature search was performed of the PubMed and EMBASE databases, for all relevant studies published until 24 September 2015. The study search was limited to patients and published in English. Keywords included "indocyanine green" and "breast cancer" and "sentinel lymph node".

The selected studies conformed to 5 inclusion criteria: regional lymphadenectomy and pathological examination including hematoxylin-eosin staining or immunohistochemistry as the referenced standard; ICG fluorescence-guided SLNB and pathological examination as the diagnostic method; the sentinel lymph node (SLN) was the study's major focus; pathological data of the reference standard and diagnostic method were both available; and included a defined subgroup of patients who underwent complete ALND after SLN dissection, regardless of the results of SLNB.

Studies were excluded for the following: reviews, meta-analyses and abstracts; animal studies; overlapping articles; lack of SLN identification rate of both SNL and patients' statistical analysis; lack of pathological examination or unavailable pathological data; ICG combined with human serum albumin or other tracers (blue dye, radioisotope) while ICG data not separately reported; or the introduction of new technology.

Data extraction and quality evaluation {#sec008}
--------------------------------------

The following data were extracted from the selected studies: first author; year of publication; country of origin; sample size; participants' characteristics, tracers, concentrations, injected volumes, injected location, tumor characteristics; ICG-related adverse reactions, average number of detected SLNs, number of patients with successful fluorescence imaging, measures of test performance of ICG fluorescence-guided SLNB including true-positive, true-negative, and false-negative results. Six researchers were involved in data extraction.

The quality of each study was quantified using the quality assessment tool for diagnostic accuracy in systemic reviews (QUADAS, score from 0 to 14)\[[@pone.0155597.ref007]\]. QUADAS is a tool for assessing the evidence-based quality of studies for diagnostic accuracy.

Statistical analysis {#sec009}
--------------------

The measures of interest for effect included detection rates, sensitivities, specificities, diagnostic odds ratios (DORs), the summary receiver operator characteristic (SROC) curve, the area under the curve (AUC), and the Q\* index. The closer the AUC is to 1.0, the better the diagnostic method. The Q\* index is a statistical value defined by the point on the SROC curve where sensitivity and specificity are equal.

The statistical heterogeneity among studies was evaluated using Cochran's Q statistic, *P*-values, and I^2^ statistics. Heterogeneity was considered significant at I^2^\> 50%, or *P*\< 0.05 (R GUI 3.0.1, R Project for Statistical Computing, USA). The sensitivity and specificity of each study was calculated by 2x2 contingency tables for correct diagnosis in the presence of lymph node metastasis.

The Mantel-Haenszel random-effects model was used to obtain the summarized detection rate, DOR, sensitivity, and specificity, considering the differences in patient characteristics, technical details, and operators' experiences. The Q\* index was subsequently produced from the SROC curve of all the included studies.

The publication bias for detection rate and diagnostic performance were explored by Harb or egger analysis, respectively, if sufficient studies were available\[[@pone.0155597.ref008]\]. *P*\< 0.05 was considered statistically significant.

Results {#sec010}
=======

We identified 38 studies from PubMed and 29 studies from EMBASE. After removal of overlapping studies, languages other than English, animal studies, technology introductions, and reviews, 55 studies remained for full review ([Fig 1](#pone.0155597.g001){ref-type="fig"}). Of these, 36 full-text articles were additionally excluded: 25 abstracts, letters, case reports, or other kinds of cancers; 6 studies without histological or immunohistological results; 3 studies in which there was no separate data regarding ICG alone (i.e., not in combination with other tracers); and 2 studies reported only the numbers of metastasized lymph nodes but not the number of patients.

![Flow chart for the selection of the included studies.](pone.0155597.g001){#pone.0155597.g001}

Finally, we included 19 qualified studies for pooling the detection rate (Tables [1](#pone.0155597.t001){ref-type="table"} and [2](#pone.0155597.t002){ref-type="table"}) \[[@pone.0155597.ref009]--[@pone.0155597.ref027]\]. The 19 studies were published from 2009 to 2015, and included a total of 2594 patients. The pooled detection rate was 0.98 (95% confidence interval \[CI\], 0.96--0.99). The heterogeneity of the pooled detection rate was low: I^2^ value was 10.1%, *P* = 0.33 ([Fig 2](#pone.0155597.g002){ref-type="fig"}). Among 19 studies, there were only 6 studies \[[@pone.0155597.ref011]--[@pone.0155597.ref013], [@pone.0155597.ref015], [@pone.0155597.ref016], [@pone.0155597.ref018]\]in which after SLNB ALND was performed plus histology or immunohistochemistry as the reference, as required for our meta-analysis.

![The pooled detection rates was 0.98 (95% confidence interval \[CI\], 0.96--0.99).](pone.0155597.g002){#pone.0155597.g002}

10.1371/journal.pone.0155597.t001

###### Nineteen studies for the pooled detection rate analysis.

![](pone.0155597.t001){#pone.0155597.t001g}

  First author                     Year   Country             Pnt/Cnt, n   Tumor stage   Other RI tracers used       Injection location                         Dose (mL; mg/mL)
  -------------------------------- ------ ------------------- ------------ ------------- --------------------------- ------------------------------------------ ------------------
  Abe                              2011   Japan               128/1        T1-2, cN0     ICG+BD                      Intradermal areola                         0.15; 5
  Aoyama                           2011   Japan               312/1        cN0           ICG only                    Subareolar & periareolar                   5; 0.125
  Chi                              2013   China               22/1         T1-2N0M0      ICG only                    Areola                                     0.5--2; 5
  Guo \[[@pone.0155597.ref012]\]   2014   China               86/1         Tis-T2        ICG+BD                      Subareolar                                 1; (1/20)
  Guo \[[@pone.0155597.ref013]\]   2014   China               36/1         Tis-T2        ICG only                    Subareolar                                 1; (1/20)
  Hirano                           2012   Japan               108/1        Tis-T4, cN0   ICG+BD cf. BD(along)        Subareolar                                 2.5; 2
  Hirche                           2012   Germany             47/1         N0-N3         ICG only                    Subareolar                                 2.2; 5
  Hirche                           2010   Germany             43/1         N0-N3         ICG only                    Subareolar                                 2.2; 5
  Hojo                             2010   Japan               141/1        Tis-T2, cN0   ICG+BD cf. ICG+RI           Tumor & sub-areolar                        2; NA
  Murawa                           2009   Germany             30/1         T1-4          ICG for all, part with RC   Periareolar                                1, 2, 3; 5
  Polom                            2012   Poland              28/1         N0-N1         ICG+RC cf. ICG+RC+HSA       Tumor or periareolar                       1; 10
  Samorani                         2015   Italy               301/1        NA            ICG+radioactive             Periareolar                                0.4--1.2; 5
  Schaafsma                        2013   Netherlands         32/1         NA            ICG+BD+RC                   Tumor or periareolar                       0.25--0.5 mg; NA
  Sugie                            2013   Japan               99/6         Tis-TX        ICG cf. BD                  Subareolar                                 0.5--1; 5
  Sugie                            2015   Japan               821/12       T1-2          ICG +RC                     Subareolar                                 1; 5
  Takeuchi                         2012   Japan               145/1        Tis-T2, cN0   ICG+BD for each             Subcutaneously into the periareolar area   1; 5
  Tong                             2014   China               96/1         Tis-T4, cN0   ICG+BD cf. BD               Subareolar                                 2; 5
  van der Vorst                    2012   Netherlands         24/1         cN0           (ICG+RC)+BD cf. no BD       Intradermal & periareolar                  1.4; 500 μmoL
  Verbeek                          2014   USA & Netherlands   95/2         T1-4          ICG+RC                      Periareolar& peritumor                     1.6; 0.39

BD, blue dye; Cnt, medical centers; HSA, human serum albumin; NA, not available or not reported; Pnt, patient; RI, radioisotope

10.1371/journal.pone.0155597.t002

###### Nineteen studies of the pooled detection rate analysis.

![](pone.0155597.t002){#pone.0155597.t002g}

                                                            SLN detection                
  -------------------------------- ------ ----------------- --------------- ------ ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abe                              2011   100% (128/128)    (1--6)          3.1          NA
  Aoyama                           2011   100% (312/312)    (1--12)         3.41         Skin pigmentation for a certain period of time
  Chi                              2013   100% (22/22)      (1--6)          2.7    Yes   No side effect
  Guo \[[@pone.0155597.ref012]\]   2014   93% (80/86)       NA              2.4    Yes   No adverse effect
  Guo \[[@pone.0155597.ref013]\]   2014   97.2% (35/36)     NA              3.6    Yes   Tatoo effect last for one week & disappear in two weeks
  Hirano                           2012   99.1% (107/108)   (0--5)          2.2          NA
  Hirche                           2012   97.9% (46/47)     (1--3)          2.0    Yes   NA
  Hirche                           2010   97.7% (42/43)     NA              2.0    Yes   NA
  Hojo                             2010   99.3% (140/141)   NA              3.8          NA
  Murawa                           2009   97% (29/30)       NA              1.75   Yes   NA
  Polom                            2012   96.4% (27/28)     (1--5)          2            NA
  Samorani                         2015   98.7% (297/301)   (1--5)          1.94         No allergic reaction, (2.5%) developed paraesthesia.(3.2%) developed seromas
  Schaafsma                        2013   100% (32/32)      NA              1.5          NA
  Sugie                            2013   99.0% (98/99)     NA              3.4          NA
  Sugie                            2015   97.2% (798/821)   NA              2.3          No serious allergic reactions related to ICG injections reported in 833 consecutive patients. Grade 1 to 2 nausea or vomiting & pain observed in 8 (1.0%) & 6 (0.7%) patients, respectively.
  Takeuchi                         2012   99.3% (144/145)   NA                           NA
  Tong                             2014   96.9% (93/96)     NA                           NA
  van der Vorst                    2012   95.8% (23/24)     NA              1.5          NA
  Verbeek                          2014   97.9% (93/95)     (1--5)          1.9          NA

Cnt, medical centers; mSLN, mean number of SLN; NA, not available or not reported; Pnt, patient

Altogether, 254 patients were included for the final analysis. The pooled sensitivity was 0.92 (95% CI, 0.85--0.96), and the specificity was 1 (95% CI 0.97--1). The heterogeneity of the pooled sensitivity analysis was low: I^2^ value was 0.0% ([Fig 3](#pone.0155597.g003){ref-type="fig"}), and the heterogeneity of the pooled specificity also had a I^2^ value of 0.0%. The pooled DOR was 311.47 (95% CI, 84.11--1153.39). The heterogeneity of the pooled studies was low: I = 0.0%, *P* = 0.97 ([Fig 4](#pone.0155597.g004){ref-type="fig"}).

![The pooled sensitivity was 0.92 (95% CI, 0.85--0.96), and the specificity was 1 (95% CI 0.97--1).](pone.0155597.g003){#pone.0155597.g003}

![The pooled DOR was 311.47 (95% CI, 84.11--1153.39).](pone.0155597.g004){#pone.0155597.g004}

The AUC of the SROC was 0.9758 ([Fig 5](#pone.0155597.g005){ref-type="fig"}), and the Q\* index = 0.93. Publication bias was not shown in any of the 19 studies analyzed early ([Fig 6A](#pone.0155597.g006){ref-type="fig"}), or the 6 studies in the meta-analysis ([Fig 6B](#pone.0155597.g006){ref-type="fig"}).

![Summary of receiver operator characteristic curves.](pone.0155597.g005){#pone.0155597.g005}

![**Funnel plots:** (A) The 19 included studies for detection rate, (B) The 6 studies with ALND confirmation.](pone.0155597.g006){#pone.0155597.g006}

Discussion {#sec011}
==========

The 3 main findings of our study are, that ICG fluorescence-guided SLNB in breast cancer has a 98% detection rate for SLN; the pooled sensitivity and specificity were relatively high and the false-negative rate was relatively low; and in the presence of metastases, the diagnostic performance of this method is good, with relatively high sensitivity and very high specificity.

SLNB has been the first choice for axillary staging of patients with early breast cancer with clinically negative axillary lymph nodes. The good diagnostic performance of SLNB is essential for cancer staging, surgical treatment, and therefore substantially influences the prognosis. Currently, blue dye and radiocolloid are the two most common methods for SLNB. Blue dye is relative simple and inexpensive. However, the detection rate of blue dye is low\[[@pone.0155597.ref028]\]. Isotope has a relatively high detection rate, but its challenges include the handling and disposal of isotopes, high expense of storage, transport and even legislative issues which limit its wide use\[[@pone.0155597.ref029]\].

The use of ICG in SLNB has some advantages compared to isotope: lower cost, fewer adverse effects, and quick transcutaneous real-time visualization (within several minutes), facilitating the localization of the incision and the detection of SLNs during the surgery. In the clinical trial NSABP (National Surgical Adjuvant Breast and Bowel Project) trial B-32 that comprised 5611 patients, the combination of blue dye and radiocolloid showed a 97.1% detection rate for SLN, compared with 89.4% for radiocolloid alone and 70.2% for blue dye alone\[[@pone.0155597.ref030]\]. In another ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance) study including 842 clinically node-negative breast cancer patients, the combination of isotope and blue dye had a 96.1% detection rate, but that of either blue dye or isotope alone was 85.6%\[[@pone.0155597.ref006]\]. Our present study showed that ICG fluorescence alone may reach a detection rate of 98%, which is even better than combined isotope and blue dye. Similarly, a recent meta-analysis comparing ICG with blue dye showed that ICG was significantly better than blue dye with regard to SLN identification (odds ratio, 18·37)\[[@pone.0155597.ref004]\].

In our present study, the pooled sensitivity was 92%, and the false-negative rate was 8%. This is comparable to the results of the NSABP B-32, in which the false-negative rate for combined blue dye and radioisotopes was 9.8%. Another study that pooled data based on 8000 patients showed that the false-negative rates were 10.9% for blue dye alone, and 8.8% for radiocolloid alone\[[@pone.0155597.ref003]\]. The accuracy of the ICG method was not superior to the combination of blue dye and radiocolloid. However, when ICG was combined with another technique, the accuracy seems to improve; a false-negative rate of 4% was observed when ICG was combined with blue dye\[[@pone.0155597.ref013]\]. This clearly showed another way to increase the sensitivity of ICG.

In the present study, high DOR and AUC suggested a good diagnostic performance for ICG fluorescence-guided SLNB. However, these results should be interpreted cautiously. For example, the pooled specificity of the present study was 100%, which is not surprising since it is impossible to have false-positive sentinel node results---if a sentinel node is pathologically involved, the axillary lymph node basin is also involved. The high specificity is clearly responsible for the high DOR, as the DOR shows the overall performance of a diagnostic test, considering both sensitivity and specificity together. The SROC and its derivatives (AUC and Q\*) are also measures of overall accuracy.

There were no severe adverse effects reported in the trials included in this study. Only two trials \[[@pone.0155597.ref009], [@pone.0155597.ref012]\]reported pigmentation, which lasted for several weeks. This makes ICG fluorescence-guided SLNB all the more attractive, when compared with the complications observed in ALND.

One main shortcoming of ICG fluorescence-guided SLNB is that indocyanine does not specially label tumor cells. Tumor-specific fluorescent probes which can selectively glow tumors, which preferably be administered topically, could significantly improve cancer detection and even removal in the surgery \[[@pone.0155597.ref031]\]: indeed, selectively highlighting tumor cells either by gamma-glutamyl hydroxymethyl rhodamine green, an enzyme commonly found in cancer cells\[[@pone.0155597.ref032]\]; or genetically label tumors in situ with green fluorescent protein\[[@pone.0155597.ref033], [@pone.0155597.ref034]\]; Spray-painting tumors by using fluorescent tumor-specific antibodies\[[@pone.0155597.ref035]\]. All of these new methods could potentially strengthen ICG fluorescence-guided SLNB, which deserves more studies in the future.

However, this meta-analysis also has several limitations. First, we only included 6 studies for the meta-analysis, mainly due to the reference standard demanded by the study design. Secondly, the technical limitations of the pathophysiological method used as the reference might have influenced the results. Finally, a false-positive rate is not possible in ICG fluorescence-guided SLNB, and this decreased the statistical power of the study.

Conclusion {#sec012}
==========

ICG fluorescence-guided SLNB is viable for detecting SLN in the presence of lymph node metastases in clinical node-negative breast cancer, and may allow the avoidance of ALND and its relatively greater complications. This study's results warrant large-scale randomized multi-center trials and long-term follow-up for confirmation.
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